Healthcare ETF: China May Control a Key Bottleneck in AI Drug Discovery
AI drug discovery (AIDD) is moving from a software story to a physical-capacity story, and a large share of that physical capacity sits in China. Before AI transforms drug discovery, it may strain the infrastructure used to test molecules worldwide. China’s biotech services sector represents one of the largest pools of that infrastructure in the […]
AI drug discovery (AIDD) is moving from a software story to a physical-capacity story, and a large share of that physical capacity sits in China. Before AI transforms drug discovery, it may strain the infrastructure used to test molecules worldwide. China’s biotech services sector represents one of the largest pools of that infrastructure in the […]
What's Your Reaction?
